Anzeige
Mehr »
Dienstag, 23.06.2026 - Börsentäglich über 12.000 News
Schuldenfrei, 1,5 Mio. Unzen Gold und Produktion ab 2027: Vor dem Ausbruch?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 918422 | ISIN: US67066G1040 | Ticker-Symbol: NVD
Tradegate
23.06.26 | 16:38
178,66 Euro
-2,14 % -3,90
1-Jahres-Chart
NVIDIA CORPORATION Chart 1 Jahr
5-Tage-Chart
NVIDIA CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
178,52178,5616:38
178,56178,6616:38
GlobeNewswire (Europe)
182 Leser
Artikel bewerten:
(1)

Sigmatic Sciences Powers AI Scientists with NVIDIA's Latest BioNeMo Agentic Capabilities

The First Agentic Operating System for Life Sciences R&D

PRESS RELEASE

Already running NVIDIA BioNeMo in production, the SigmaticOS now leverages NVIDIA's latest agentic innovations to connect AI agents, scientific software, and laboratory systems into traceable lab-in-the-loop discovery workflows.

Fort Lauderdale, Florida, USA, June 23, 2026 - Sigmatic Sciences, the first agentic operating system for life sciences R&D, today announced integration of NVIDIA BioNeMo Agent Toolkit within SigmaticOS, strengthening its ability to deploy AI Scientists that can reason, plan, and execute across the full scientific discovery lifecycle.

Powerful AI agents alone do not create scientific breakthroughs. They need scientific context, trusted data, specialized tools, and laboratory connectivity to operate effectively. SigmaticOS provides a scientific operating system that transforms hundreds of AI agents into an AI Scientist capable of orchestrating data, models, software, and experiments into a single traceable workflow. This enables research teams to move beyond isolated AI assistance and toward scalable, reproducible scientific discovery, with scientists always in the driver's seat.

SigmaticOS has leveraged NVIDIA BioNeMo and Nemotron models in production since its inception. With the release of BioNeMo Agent Toolkit, SigmaticOS further expands its ability to orchestrate biological AI models, scientific software, enterprise data, and laboratory systems within a single coordinated research environment. Enabling governance, traceability, and scientific guardrails resulting in an agentic AI that can move beyond isolated experimentation and into real-world scientific operations.

NVIDIA BioNeMo Agent Toolkit provides the biological AI foundation for this transformation, delivering specialized models, agent frameworks, and infrastructure designed for life sciences. SigmaticOS provides the operating system that puts those capabilities to work, connecting AI agents to the tools, data, and laboratory environments required to conduct rigorous scientific research.

"Powerful AI agents are only part of the equation," saidKevin Cramer, Founder and CEO of Sigmatic Sciences. "The AI Scientist we have built ensures every AI agent has the scientific context, access to trusted data, the ability to use specialized scientific tools, and a direct connection to laboratory execution. The world in which they operate is exactly what SigmaticOS provides."

Through SigmaticOS, the capabilities of NVIDIA BioNeMo Agent Toolkit are orchestrated alongside more than 300 specialized scientific agents and connected across the entire discovery stack. This includes proprietary experimental data, any ELN/LIMS and laboratory automation infrastructure like Sapio Sciences, scientific literature and data resources from Elsevier, structural chemistry capabilities from the Cambridge Crystallographic Data Centre (CCDC), and advanced simulation platforms from Simulations Plus.

The platform also incorporates domain-specific biological AI models from the NVIDIA BioNeMo ecosystem, including OpenFold3 and Boltz-2 for biomolecular structure prediction, RNApro for RNA structure analysis, and ReaSyn for synthesizability assessment.

The result is a true lab-in-the-loop discovery system where an AI Scientist can continuously learn from experimental outcomes, refine hypotheses, and coordinate subsequent investigations. By connecting biological AI directly to scientific software and laboratory infrastructure, SigmaticOS helps researchers shorten the path from idea to experiment to insight.

Kevin Cramer added: "We've been running NVIDIA BioNeMo in production from the beginning, and the latest agentic capabilities strengthen our vision for AI Scientists that work alongside human researchers. SigmaticOS provides the scientific operating system. Together, we're creating a new model for discovery where AI can reason across data, use specialized scientific tools, and interact directly with the laboratory as part of a single traceable workflow."

Sigmatic Sciences will showcase its BioNeMo-powered AI Scientist workflows at the BIO International Convention, June 22-25 in San Diego.

-END-

For more information please contact:

Sigmatic Sciences
Kevin Cramer, Founder and CEO
Mike Hampton, Chief Commercial Officer
Dave Cooney, Head of GTM
info@sigmaticsciences.com

ICR Healthcare
Jessica Hodgson / Ashley Tapp
SigmaticSciences@icrhealthcare.com

To book a demonstration of SigmaticOS please contact:
dave.cooney@sigmaticsciences.com

About Sigmatic Sciences

Sigmatic Sciences, formerly HelixAI and a proud Sapio Sciences Company, is dedicated to transforming R&D by unifying tools and autonomous processes in a single platform, enabling scientists to deliver better medicines, faster.

We have created the Sigmatic Operating System (SigmaticOS), the only complete labin-the-loop platform for all scientists, allowing research to move from copilot to autopilot. SigmaticOS orchestrates 100+ agents across in silico workflows, lab automation, and model training with full traceability. By integrating scientific data from public, private and client sources with unlimited autonomous computation, SigmaticOS takes the pain out of drug discovery, closing the loop between computation and the bench, and putting human scientists into the driving seat.

Sigmatic Sciences is led by a team with decades of experience in science, AI and bioinformatics and backed by one of Europe's leading healthcare investors, GHO Capital.

Find out more online at: https://www.sigmaticsciences.com/

Follow us on LinkedIn

About Lab-in-the-loop

Lab-in-the-loop is an iterative research framework that accelerates drug discovery by creating an iterative feedback cycle between computational models and physical experiments. In silico tools generate scientific hypotheses, which are tested in automated labs, with results being analyzed and used in refining the AI tools for the next cycle.


© 2026 GlobeNewswire (Europe)
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.